Prostate Cancer
An Introduction to Prostate Cancer
The management of prostate cancer has evolved rapidly over the last decade. There are now several approved treatments in the castration-resistant treatment setting, delivering significant benefits like overall survival rate. The androgen receptor-targeting agents are also now proving effective in the hormone-sensitive setting.
Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
With the European Society for Medical Oncology (ESMO) Congress 2026 fast approaching, attention is turning to Madrid, where the meeting is held from 23–27th October. Whether you are joining onsite or via the virtual platform, the three Presidential Symposia are the sessions not to miss. This year they carry 12 late-breaking abstracts (LBAs) spanning melanoma, lung, genitourinary, gastrointestinal, gynecological and rare cancers. With close to 300 scientific and educational sessions to choose from, we know the programme can feel overwhelming. So we have put together a quick guide to the headline sessions: when and where they run, who is presenting, and links to explore each one in the programme planner, so you can decide which to prioritize.
The European Society for Medical Oncology (ESMO) Congress 2026 promises a compelling program of clinical data, spanning personalized cancer vaccines, next-generation antibody–drug conjugates (ADCs) and novel approaches to targeted therapy and immunotherapy. With several studies already generating excitement following positive topline announcements, all eyes will be on the full results and their potential implications for clinical practice. Below, we highlight the 12 presidential abstracts to watch, the key findings to look out for and the questions these studies could help answer.
Join us as leading experts discuss key data from the Plenary, Late-breaking and top oral sessions across each major disease area at ASCO 2026 touchONCOLOGY coverage of ASCO 2026 2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought together the global oncology ...
Could upfront PARP inhibition transform outcomes for patients with HRR-altered metastatic hormone-sensitive prostate cancer? New data from the landmark TALAPRO-3 trial show meaningful rPFS gains with talazoparib plus enzalutamide, reinforcing the importance of early biomarker testing. [touchplayvideo video_id="m9...
Landmark abstracts across localized and advanced prostate cancer presented at ASCO 2026 addressed treatment intensification, biomarker-driven therapy, radiotherapy modality comparisons, and novel radioligand strategies. In this piece we examine four studies that reflect important shifts in prostate cancer management, influencing both near-term treatment pathways and future: PROTEUS, TALAPRO-3, COMPPARE and ProstACT Global.
The five selected Plenary late-breaking abstracts at the ASCO 2026 Annual Meeting in Chicago showcased some of the meeting’s most practice-influencing data. Across prostate cancer, sarcoma, lung cancer and pancreatic cancer, these phase 3 studies demonstrated meaningful improvements in survival outcomes, highlighting the growing impact of perioperative intensification, precision oncology and novel targeted therapies in difficult-to-treat disease settings.
The 38th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona brought together over 9,400 participants, marking a major milestone. The meeting highlighted major advances in oncologic imaging and theranostics, with a strong emphasis on precision medicine and combination treatment strategies. Across plenary sessions, debates, and late-breaking discussions, the meeting underscored how nuclear medicine is increasingly central to cancer diagnosis, treatment selection, and therapeutic delivery.
See who the oncology community selected as the rising stars of 2026!
In this Future Leaders interview, Dr Gómez Rivas discusses the mentors who shaped his career, the values that sustain a life in surgery and research, and the importance of mentorship, teamwork and resilience for the next generation of urologists.
At EAU26, Dr Juan Gómez Rivas reflected on a period of rapid transformation in the field. Across mentorship, technology and precision medicine, Dr Gómez Rivas believes the field is entering a new era. For urologists, he says, the message is simple: embrace innovation, collaborate widely and keep patients at the centre of every advance.
At EAU26, Dr Karen Buch-Olsen and Professor Mads Hvid Aaberg Poulsen shared early insights from the PRISMA PET trial, a randomized study comparing conventional sodium fluoride PET CT with PSMA PET CT in newly diagnosed, high-risk prostate cancer patients.
Microplastics have been detected across the human body – but what they mean for cancer risk remains unclear. At the recent ASCO GU26, presented early data suggesting these particles are not only present in the prostate, but may be more concentrated in tumour tissue. The findings raise provocative questions about environmental exposures and carcinogenesis, while underscoring just how much remains unknown.
The 2026 ASCO Genitourinary Cancers Symposium showcased pivotal advances across renal, prostate and bladder cancers. Key late-breaking trials across kidney, prostate and bladder cancer highlighted promising combinations, novel targeted therapies and innovative radioligand approaches, demonstrating improved disease control, progression-free survival and ...
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
Fresh data from the ESMO 2025 Congress reveal major shifts in prostate and kidney cancer treatment. From radioligand therapy entering first-line prostate cancer to the first targeted AKT strategy in PTEN-deficient disease, and new benchmarks in RCC with LenCabo and RAMPART, the landscape is rapidly evolving.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
